FDA, Zepbound and Mounjaro drugs
Off-brand versions of Lilly weight loss drug must be pulled off market, could mean higher prices
The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved and that specialty pharmacies and online companies need to stop selling off-brand versions of the weight-loss drugs. The FDA has issued warnings against the off-brand versions, citing safety concerns.
The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...
The FDA's final rule defines a nonprescription drug product with an ACNU as one that could be marketed without a prescription if the manufacturer implements an additional condition to ensure ...
An antidepressant medication named duloxetine has been recalled by the U.S. Food and Drug Administration (FDA) due to the presence of carcinogenic chemicals. The drug was voluntarily recalled by ...
Buy-herbal.com has issued a recall of all lots within current expiration dates of Nhan Sam Tuyet Lien Truy Phong Hoan ...
The US Food and Drug Administration on Monday approved Hikma Pharmaceuticals’ generic version of Novo Nordisk’s diabetes drug, Victoza, clearing the way for the launch of another copy of the ...
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, ...
233,003 bottles of the drug, named Duloxetine, were voluntarily recalled by their distributor, Rising Pharmaceuticals, Inc.—based in East Brunswick, New Jersey—on November 19. The recall was ...
I found that so many people were making their own GLP-1s and taking smaller amounts than normally prescribed,” she said. “I ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback